니볼루맙 주사제 시장 규모, 점유율 및 성장 분석 : 적응증별, 치료법별, 최종사용자별, 유통 채널별, 용량 강도별, 지역별 - 업계 예측(2026-2033년)

Global Nivolumab Injection Market size was valued at USD 874.5 Million in 2024 and is poised to grow from USD 925.22 Million in 2025 to USD 1452.55 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global nivolumab injection market represents a significant sector focused on a monoclonal antibody that inhibits PD-1, enabling the immune system to target malignant cells effectively. This drug serves as a vital treatment for conditions such as melanoma, non-small cell lung cancer, and renal cell carcinoma, generating substantial revenue for manufacturers like Bristol-Myers Squibb. The expanding reimbursement landscape is a key growth driver, as insurers increasingly acknowledge its impact on overall survival, particularly in metastatic melanoma, resulting in more frequent inclusion in formularies. Additionally, AI-driven data analytics is reshaping pricing strategies within this market by utilizing real-world patient data and competitor insights to create flexible, tiered pricing models that align with disease severity and treatment duration, ultimately enhancing patient access and sustaining market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nivolumab Injection market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nivolumab Injection Market Segments Analysis

The global nivolumab injection market is segmented by indication, therapy type, end user, distribution channel, dosage strength and region. Based on indication, the market is segmented into Melanoma, Lung Cancer, Renal Cell Carcinoma and Others. Based on therapy type, the market is segmented into Monotherapy and Combination Therapy. Based on end user, the market is segmented into Hospitals and Oncology Clinics. Based on distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on dosage strength, the market is segmented into 40 mg/4 mL, 100 mg/10 mL and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nivolumab Injection Market

The expansion of approved therapeutic uses for nivolumab across various oncology indications is a key factor driving growth in the global market. As healthcare providers increasingly adopt this treatment for a broader range of patients, pharmaceutical companies intensify their promotional efforts, which further enhances market presence. This diversification diminishes dependence on a single disease area, boosting physician confidence and fostering its integration into combination therapies. Such dynamics create consistent demand and affirm the drug's significance within advancing treatment protocols. Additionally, growing clinical evidence demonstrating long-term survival advantages bolsters payer acceptance, leading to broader reimbursement and encouraging its inclusion in standard treatment regimens.

Restraints in the Global Nivolumab Injection Market

The high price point of nivolumab presents a significant financial challenge for healthcare budgets, making it less accessible for patients, especially in resource-limited settings. Insurance providers frequently impose strict reimbursement requirements, necessitating comprehensive evidence of clinical efficacy, which can lead to delays in starting treatment and hinder market growth. This economic strain limits the widespread uptake of the medication, particularly in developing regions where healthcare resources favor more cost-effective options. Furthermore, the requirement for routine infusion appointments contributes to additional indirect costs for both patients and healthcare providers, further impacting treatment choices and overall market dynamics.

Market Trends of the Global Nivolumab Injection Market

The Global Nivolumab Injection market is witnessing a notable surge, driven by the rising trend of immunotherapy combinations. Healthcare professionals are increasingly incorporating nivolumab with various checkpoint inhibitors, targeted therapies, and chemotherapy treatments to improve response longevity and address resistance challenges. This trend is backed by emerging clinical research highlighting the enhanced efficacy of these combination therapies, prompting pharmaceutical companies to focus on co-development strategies. Consequently, market players are diversifying their product offerings and forming strategic partnerships, leading to evolving prescribing practices and expanding the potential patient base for nivolumab, thereby reshaping the landscape of oncology treatments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Nivolumab Injection Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Melanoma
• Lung Cancer
• Renal Cell Carcinoma
• Others

Global Nivolumab Injection Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Monotherapy
• Combination Therapy

Global Nivolumab Injection Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Clinics

Global Nivolumab Injection Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Nivolumab Injection Market Size by Dosage Strength & CAGR (2026-2033)

• Market Overview
• 40 mg/4 mL
• 100 mg/10 mL
• Others

Global Nivolumab Injection Market Size by Geography & CAGR (2026-2033)

• Market Overview
• Developed Markets
• Emerging Markets

Global Nivolumab Injection Market Size & CAGR (2026-2033)

• North America (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • US
  • Canada
• Europe (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Junshi Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Thera Solutions Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations